AN2 Therapeutics | Investor Presentation Deck

Slide schematic 6/6

callout 2/2 image 1/1 list 1/1 paragraph 1/1 title 1/1

Components 6

primary primary illustration bullet paragraph headline

Tools 1

Elevating QOL-b respiratory domain, change from baseline to month 6 as the primary endpoint. Submitted statistical analysis plan to FDA (1Q25). Goal to Unblind 97 Patients enrolled in truncated Phase 3 (2Q25

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

Focuses on PRO (Patient Reported Outcomes) as a primary endpoint for the EBO-301 trial.